This post is part of a series of blogs illuminating aspects of racial equity in childbirth and highlighting promising practices to ensure access to a safe, empowering, healthy, and positive birth for all people.
This post has been written by Katy Kozhimannil as part of a collaborative research partnership with Rachel Hardeman and Rebecca Polston, supported by the Robert Wood Johnson Foundation's Interdisciplinary Research Leaders Program.
We’re hearing a lot these days about potential downstream effects of current efforts to repeal and replace Obamacare (the Senate’s Better Care Reconciliation Act and the House’s American Health Care Act). Recent media coverage highlights how this legislation may affect women and their babies. A flurry of attention has been paid to a seminal 1996 study, aptly titled “Saving Babies,” which showed how Medicaid coverage during pregnancy reduces infant mortality (death during the baby’s first year of life). This research lays bare the reality of how important a mom’s care is to her baby’s health, and how much is at stake in current health policy debates.
The death of an infant is almost always met with deep expressions of sympathy and condolences. Though appropriate, these are not enough: they do not prevent future deaths or change America’s ongoing problem with infant mortality.
Now is not the time to go backward in our policy. The data show that American babies are more likely to die than babies in many other countries across the world. The 2016 US infant mortality rate (5.8 deaths per 1000 live births) is higher than 56 other countries. It’s not just the richest, most developed countries that have us beat. Our infant mortality rate is higher than Latvia (5.3 deaths per 1000 live births), where per-capita income is $14,630 versus $56,180 in the United States.
Though US infant death rates have been slightly declining over the past couple of decades, they’re falling more slowly in the United States than in other wealthy countries, and have stagnated in recent years.
Moreover, racial disparities in infant mortality are staggering and shameful. Black infants are twice as likely as white infants to die before their first birthday. What’s worse, a JAMA Pediatrics study published this month shows that the black-white disparities in infant mortality have increased over the past 3 years.
We can do something about this, but it will take more than expressions of grief. Change starts with mom, and to comprehensively address infant mortality, the focus must shift from the tragedy of babies’ untimely death to more complete and consistent care of their mothers before, during, and after pregnancy.
An Increased Focus on Mom
Many well-meaning efforts to reduce infant mortality focus almost exclusively on the baby. Clearly, that’s not enough. To see an infant’s death in the broader context of a mother, family, and community, it is instructive to consult evidence from the international context. For example, the theory of change that guides interventions to achieve Millennium Development Goals related to child survival focuses directly on maternal health and well-being, including her access to “practices that save lives,” “enhanced interactions between families and frontline workers,” and a “conducive policy environment.”
The “practices that save lives” have been compiled and well-documented by the World Health Organization and the World Bank, and US health plans, clinicians, administrators, and policy-makers would do well to consult these lists of evidence-based interventions to reduce perinatal mortality during pregnancy and at the time of childbirth. However, for women to access these clinical services, they need to have financial, logistical, cultural, and geographic access to the care they need. We will discuss these in greater detail in future blog posts.
In the context of current political debates in U.S. healthcare policy, the evidence base on two topics is particularly notable: contraceptive access and adequate prenatal care. International evidence shows a link between family planning and fewer infant deaths via birth spacing and preventing high risk births to younger and older mothers. Additionally, a Cochrane review shows that infants whose mothers attended fewer prenatal visits may be at increased risk of dying, compared to those whose moms received standard prenatal care. While these studies were conducted largely in low- and middle-income country settings. The findings may well apply to many low-income U.S. women who struggle to access adequate prenatal care.
These examples illustrate that change requires leadership from public programs, health plans, clinicians, and healthcare delivery organizations. Current health policy debates — especially as they relate to Medicaid programs, contraceptive access, and the inclusion of maternity coverage as an “essential benefit” in health plans, bring this discussion into sharp focus. Reductions in access to insurance, contraception, and prenatal care may risk increases in infant mortality.
Our next blog post highlights specific steps that these stakeholders can take to improve maternal and infant health, and to directly address racial disparities in access to, experiences of, and outcomes of care.
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Pulmonary Hypertension Subtypes Show Distinct PA Flow Hemodynamics
March 21st 2025Investigators used 4D flow cardiovascular magnetic resonance imaging to search for differences between pulmonary artery (PA) remodeling in pulmonary arterial hypertension and other types of pulmonary hypertension.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
FDA Approves Vutrisiran to Mitigate Cardiomyopathy-Related Risks and Conditions
March 21st 2025In a recent decision, the FDA approved vutrisiran (amvuttra), making it the only approved therapy for adults with hereditary transthyretin-mediated amyloidosis (ATTR-CM) or wild-type cardiomyopathy.
Read More
Streamlining "Brain-to-Vein" Time, Patient Selection, Imperative for Implementing CAR T for MM
March 21st 2025Ajai Chari, MD, University of California San Francisco, explores the challenges that accompany integrating chimeric antigen receptor (CAR) T-cell therapies into multiple myeloma treatment.
Read More